The aging myostatin null phenotype: reduced adiposity, cardiac hypertrophy, enhanced cardiac stress response, and sexual dimorphism
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The natural aging process results in the physiological decline of multiple tissues and organ systems. Changes commonly occur with middle age and include decreased skeletal muscle mass, bone mineral density, cardiac output, and insulin sensitivity, and increased adiposity, all of which can contribute to the onset of sarcopenia, osteoporosis, heart failure, or type 2 diabetes. Recent studies suggest that myostatin may influence many of these systems. We therefore sought to determine whether they are affected by aging, especially in ‘middle-aged’Mstn−/−mice (12–20 months old (m.o.)). Although body weights were similar in wild-type (WT) and Mstn−/−mice, lean fat-free mass and skeletal muscles composed of predominantly type I, II, and mixed fibers were significantly heavier in Mstn−/−mice. These differences were accompanied by lower total adiposity, especially in female mice, white and brown fat pad weights, and adipocyte size. Hearts were heavier in Mstn−/−mice across a large age range (3–24 m.o.) and exhibited signs of dilated cardiomyopathy at rest, which include lower strain measurements compared with WT myocardium. However,Mstn−/−mice responded better to isoproterenol stress tests with greater increases in fractional shortening and ejection fraction—differences that were again more apparent in females and which are consistent with physiological cardiac hypertrophy. Spleens and kidneys were also smaller, although histologically normal, in Mstn−/−mice. These data together suggest that attenuating myostatin could potentially prevent or possibly treat pathological conditions that develop with age. Additional studies are nevertheless needed to definitively assess potential risks to cardiac function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding sarcopenia as a geriatric syndrome
Cruz-Jentoft, A. J., Landi, F., Topinková, E., & Michel, J.-P. (2010) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328333c1c1 · Cited by 602
Guo, T., Jou, W., Chanturiya, T., Portas, J., Gavrilova, O., & McPherron, A. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004937 · Cited by 402 · cited 4×
“MstnK/K mice do not become obese when fed a high-fat diet (Wilkes et al. 2009) as the increased musculature consumes circulating carbohydrates and prevents the de novo synthesis of triglycerides (Guo et al. 2009).”
BackgroundInfluentialMyostatin Knockout in Mice Increases Myogenesis and Decreases Adipogenesis
Lin, J., Arnold, H. B., Della-Fera, M. A., Azain, M. J., Hartzell, D. L., & Baile, C. A. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6500 · Cited by 313 · cited 2×
“As with aging MstnK/K mice, liver weights are also smaller in these mice as well as in juvenile (1–3 m.o.) MstnK/K mice (Lin et al. 2002), which is consistent with increased negative feedback on pituitary GH, the primary regulator of liver size (Ohlsson et al. 2009).”
BackgroundGenetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure
Heineke, J., Auger-Messier, M., Xu, J., Sargent, M., York, A., Welle, S., & Molkentin, J. D. (2010) · Circulation · doi:10.1161/circulationaha.109.882068 · Cited by 238 · cited 1×
“It is surprising, therefore, that some studies have failed to identify cardiac hypertrophy in MstnK/K mice (Morissette et al. 2006, Cohn et al. 2007, Heineke et al. 2010) especially as overexpressing myostatin stimulates cardiac Journal of Endocrinology (2012) 213, 263–275 atrophy (Artaza et al.…”
ResultPharmacological strategies for muscular dystrophy
Khurana, T. S., & Davies, K. E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1085 · Cited by 225
Transcriptional effects of chronic Akt activation in the heart
Cook, S. A., Matsui, T., Li, L., & Rosenzweig, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201462200 · Cited by 199
LeBrasseur, N. K., Schelhorn, T. M., Bernardo, B. L., Cosgrove, P. G., Loria, P. M., & Brown, T. A. (2009) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glp068 · Cited by 180 · cited 2×
“Other studies suggest that myostatin blockade can enhance skeletal muscle regeneration, exercise performance, and whole-body metabolism in senescent mice (Siriett et al. 2007, Yablonka-Reuveni 2007, Lebrasseur et al. 2009).”
BackgroundMyostatin activation in patients with advanced heart failure and after mechanical unloading
George, I., Bish, L. T., Kamalakkannan, G., Petrilli, C. M., Oz, M. C., Naka, Y., Lee Sweeney, H., & Maybaum, S. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq039 · Cited by 136
Resting Echocardiographic Parameters After Cessation of Regular Endurance Training
Pavlik, G., Bachl, N., Wollein, W., Lángfy*, G., & Prokop, L. (1986) · International Journal of Sports Medicine · doi:10.1055/s-2008-1025764 · Cited by 18 · cited 1×
“In fact, EF and FS values rise to expected levels when elite athletes stop training (Pavlik et al. 1986, Snyder et al. 1995) as the reductions are due to reduced relative preload in the presence of enhanced after load at rest (Abergel et al. 2004), which was interestingly demonstrated in MstnK/K…”
Background
Cited by
Loffredo, F. S., Steinhauser, M. L., Jay, S. M., Gannon, J., Pancoast, J. R., Yalamanchi, P., Sinha, M., Dall’Osso, C., Khong, D., Shadrach, J. L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.015 · Cited by 948
“Interestingly, although myostatin null mice have not consistently demonstrated important changes in cardiac mass during aging (Cohn et al., 2007; Jackson et al., 2012), treatment with a soluble ActRIIB antagonist leads to increased skeletal and cardiac muscle mass, suggesting that the cardiac…”
InfluentialAdaptive thermogenesis in adipocytes: Is beige the new brown?
Wu, J., Cohen, P., & Spiegelman, B. M. (2013) · Genes & Development · doi:10.1101/gad.211649.112 · Cited by 828
Sarcopenic obesity: how do we treat it?
Bouchonville, M. F., & Villareal, D. T. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/01.med.0000433071.11466.7f · Cited by 141
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
Self-citationSmad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice
Winbanks, C. E., Murphy, K. T., Bernardo, B. C., Qian, H., Liu, Y., Sepulveda, P. V., Beyer, C., Hagg, A., Thomson, R. E., Chen, J. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4976 · Cited by 95
Self-citation
Metadata
- Authors
- Jackson, M. F., Luong, D., Vang, D. D., Garikipati, D. K., Stanton, J. B., Nelson, O. L., & Rodgers, B. D.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2012-03-19
- Volume
- 213
- Issue
- 3
- Pages
- 263-275
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2097099452
- Cited by
- 64
- References
- 9
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The aging myostatin null phenotype: reduced adiposity, cardiac hypertrophy, enhanced cardiac stress response, and sexual dimorphism. https://app.cochat.ai/papers/10.1530/joe-11-0455
- The paper
- Jackson, M. F., Luong, D., Vang, D. D., Garikipati, D. K., Stanton, J. B., Nelson, O. L., & Rodgers, B. D. (2012). The aging myostatin null phenotype: reduced adiposity, cardiac hypertrophy, enhanced cardiac stress response, and sexual dimorphism. Journal of Endocrinology. https://doi.org/10.1530/joe-11-0455
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.